Arkolith/Insider Trading/LENZ/Form 4

Schimmelpennink Evert B.

President, CEO and Secretary, DirectorLENZ Therapeutics, Inc. (LENZ) · full profile →Form 4 · filed Mar 25, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
4
0 non-derivative · 4 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 21, 2024Grant(A)316K—$0316K
Mar 21, 2024Grant(A)83K—$083K
Mar 21, 2024Grant(A)387K—$0387K
Mar 21, 2024Grant(A)475K—$0475K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001815776-24-000020) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML